Felipe K Hurtado

Felipe K Hurtado

Daiichi-Sankyo Co., Ltd - Tokyo / Japan
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4507893
person_outline Felipe K Hurtado's MOST POPULAR ARTICLES
1-) Discovery of orally active inhibitors of Brahma homolog (BRM)/SMARCA2 ATPase activity for the treatment of Brahma related gene 1 (BRG1)/SMARCA4-mutant cancersJPN Papillon, K Nakajima, CD Adair, J Hempel, AO Jouk, RG Karki, ...Journal of Medicinal Chemistry 61 (22), 10155-10172, 2018762018
2-) ★ Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion studyM Fischer, L Moreno, DS Ziegler, LV Marshall, CM Zwaan, MS Irwin, ...The Lancet Oncology 22 (12), 1764-1776, 2021472021
3-) Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients with advanced NSCLCA Chiappori, CC Williams, BC Creelan, T Tanvetyanon, JE Gray, ...Journal of Clinical Oncology 36 (Suppl 15), Abstr # 9089, 201847*2018
4-) ASCEND-7: Efficacy and safety of ceritinib treatment in patients with ALK-positive non-small cell lung cancer metastatic to the brain and/or leptomeningesLQM Chow, F Barlesi, EM Bertino, MJ van der Bent, HA Wakelee, PY Wen, ...Clinical Cancer Research 28 (12), 2506-2516, 2022422022
5-) Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancerAA Chiappori, B Creelan, T Tanvetyanon, JE Gray, EB Haura, R Thapa, ...Clinical Cancer Research 28 (11), 2313-2320, 2022422022